Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

C. T. M. M. de Kanter; A. P. H. Colbers; M. I. Blonk; C. P. W. G. M. Verweij-van Wissen; B. J. J. W. Schouwenberg; J. P. H. Drenth; D. M. Burger

doi:10.1093/jac/dkt032

Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkt032 ◽

2013 ◽

Vol 68 (6) ◽

pp. 1415-1422 ◽

Cited By ~ 4

Author(s):

C. T. M. M. de Kanter ◽

A. P. H. Colbers ◽

M. I. Blonk ◽

C. P. W. G. M. Verweij-van Wissen ◽

B. J. J. W. Schouwenberg ◽

...

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Protease Inhibitor ◽

Healthy Volunteers ◽

Proton Pump ◽

Hcv Protease ◽

Drug Drug Interaction ◽

Clinically Significant

Download Full-text

Faculty of 1000 evaluation for Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717958759.793470403 ◽

2013 ◽

Author(s):

Glenn Tillotson

Keyword(s):

Drug Interaction ◽

Protease Inhibitor ◽

Healthy Volunteers ◽

Integrase Inhibitor ◽

Hiv Integrase ◽

Hcv Protease ◽

Drug Drug Interaction ◽

Clinically Significant

Download Full-text

Lack of a Clinically Significant Drug–Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Clinical Infectious Diseases ◽

10.1093/cid/cis824 ◽

2012 ◽

Vol 56 (2) ◽

pp. 300-306 ◽

Cited By ~ 22

Author(s):

Clara T. M. M. de Kanter ◽

Maren I. Blonk ◽

Angela P. H. Colbers ◽

Bas J. J. W. Schouwenberg ◽

David M. Burger

Keyword(s):

Drug Interaction ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Protease Inhibitor ◽

Healthy Volunteers ◽

Integrase Inhibitor ◽

Hiv Integrase ◽

Drug Drug Interaction ◽

Clinically Significant

Download Full-text

Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

European Journal of Drug Metabolism and Pharmacokinetics ◽

10.1007/s13318-020-00649-x ◽

2020 ◽

Author(s):

Maxime Le Merdy ◽

Ming-Liang Tan ◽

Dajun Sun ◽

Zhanglin Ni ◽

Sue-Chih Lee ◽

...

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Interaction Mechanism ◽

Pharmacokinetic Modeling ◽

Physiologically Based Pharmacokinetic Modeling ◽

Modeling Approach ◽

Physiologically Based Pharmacokinetic ◽

Physiologically Based ◽

Drug Drug Interaction

Download Full-text

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.997 ◽

2021 ◽

Author(s):

Ashit Trivedi ◽

Winnie Sohn ◽

Pegah Jafarinasabian ◽

Hanze Zhang ◽

Bianca Terminello ◽

...

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Healthy Subjects ◽

Interaction Study ◽

Drug Interaction Study ◽

Omecamtiv Mecarbil ◽

Drug Drug Interaction ◽

Pharmacokinetic Drug

Download Full-text

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3020-z ◽

2016 ◽

Vol 78 (1) ◽

pp. 41-49 ◽

Cited By ~ 12

Author(s):

Vikram Malhi ◽

Dawn Colburn ◽

Sarah J. Williams ◽

Cornelis E. C. A. Hop ◽

Mark J. Dresser ◽

...

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Interaction Study ◽

Drug Interaction Study ◽

P Glycoprotein ◽

Cytochrome 450 ◽

Drug Drug Interaction ◽

Clinical Drug

Download Full-text

Changes in gastric pH and in pharmacokinetics of ulipristal acetate a drug-drug interaction study using the proton pump inhibitor esomeprazole

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp201789 ◽

2013 ◽

Vol 51 (01) ◽

pp. 26-33 ◽

Cited By ~ 16

Author(s):

Oliver Pohl ◽

Ian Osterloh ◽

Véronique Lecomte ◽

Jean-Pierre Gotteland

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Gastric Ph ◽

Interaction Study ◽

Drug Interaction Study ◽

Ulipristal Acetate ◽

Drug Drug Interaction

Download Full-text

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2016.22.8.939 ◽

2016 ◽

Vol 22 (8) ◽

pp. 939-947 ◽

Cited By ~ 14

Author(s):

Michael A. Serbin ◽

Gregory F. Guzauskas ◽

David L. Veenstra

Keyword(s):

Drug Interaction ◽

Proton Pump Inhibitor ◽

Clinical Outcomes ◽

Proton Pump ◽

Meta Analysis ◽

Drug Drug Interaction ◽

Inhibitor Drug

Download Full-text

Faculty Opinions recommendation of Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162614.624823 ◽

2009 ◽

Author(s):

Peter Katelaris

Keyword(s):

Proton Pump Inhibitor ◽

Healthy Volunteers ◽

Proton Pump ◽

Proton Pump Inhibitor Therapy ◽

Inhibitor Therapy ◽

Withdrawal Of Therapy

Download Full-text

Effect of Rabeprazole (E3810), a Novel Proton Pump Inhibitor, on Intragastric pH in Healthy Volunteers.

The Tohoku Journal of Experimental Medicine ◽

10.1620/tjem.186.43 ◽

1998 ◽

Vol 186 (1) ◽

pp. 43-50 ◽

Cited By ~ 6

Author(s):

Michio Hongo ◽

Takayuki Kimpara ◽

Satoshi Moriyama ◽

Shuichi Ohara ◽

Shin-ichiro Sone ◽

...

Keyword(s):

Proton Pump Inhibitor ◽

Healthy Volunteers ◽

Proton Pump ◽

Intragastric Ph

Download Full-text

Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

Clinical Therapeutics ◽

10.1016/j.clinthera.2013.02.015 ◽

2013 ◽

Vol 35 (3) ◽

pp. 226-235 ◽

Cited By ~ 19

Author(s):

Sreeraj Macha ◽

Regina Sennewald ◽

Peter Rose ◽

Katja Schoene ◽

Sabine Pinnetti ◽

...

Keyword(s):

Drug Interaction ◽

Healthy Volunteers ◽

Sodium Glucose Cotransporter ◽

Drug Drug Interaction

Download Full-text

Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

Faculty of 1000 evaluation for Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.

Lack of a Clinically Significant Drug–Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Changes in gastric pH and in pharmacokinetics of ulipristal acetate  a drug-drug interaction study using the proton pump inhibitor esomeprazole

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis

Faculty Opinions recommendation of Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.

Effect of Rabeprazole (E3810), a Novel Proton Pump Inhibitor, on Intragastric pH in Healthy Volunteers.

Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

Changes in gastric pH and in pharmacokinetics of ulipristal acetate a drug-drug interaction study using the proton pump inhibitor esomeprazole